TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $60.10 million. The enterprise value is $31.79 million.
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 60.10 million shares outstanding. The number of shares has increased by 129.43% in one year.
| Current Share Class | 55.82M |
| Shares Outstanding | 60.10M |
| Shares Change (YoY) | +129.43% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 0.21% |
| Owned by Institutions (%) | 42.05% |
| Float | 50.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.37 |
| Forward PS | 9.96 |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.65, with a Debt / Equity ratio of 0.95.
| Current Ratio | 6.65 |
| Quick Ratio | 6.41 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -45.59 |
Financial Efficiency
Return on equity (ROE) is -80.95% and return on invested capital (ROIC) is -31.89%.
| Return on Equity (ROE) | -80.95% |
| Return on Assets (ROA) | -29.62% |
| Return on Invested Capital (ROIC) | -31.89% |
| Return on Capital Employed (ROCE) | -69.61% |
| Weighted Average Cost of Capital (WACC) | 5.62% |
| Revenue Per Employee | $64,338 |
| Profits Per Employee | -$875,387 |
| Employee Count | 142 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.88% in the last 52 weeks. The beta is 1.06, so TCRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | -21.88% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 1.36 |
| Relative Strength Index (RSI) | 37.66 |
| Average Volume (20 Days) | 946,288 |
Short Selling Information
The latest short interest is 942,877, so 1.57% of the outstanding shares have been sold short.
| Short Interest | 942,877 |
| Short Previous Month | 1.89M |
| Short % of Shares Out | 1.57% |
| Short % of Float | 1.87% |
| Short Ratio (days to cover) | 0.95 |
Income Statement
In the last 12 months, TCRX had revenue of $9.14 million and -$124.31 million in losses. Loss per share was -$0.96.
| Revenue | 9.14M |
| Gross Profit | -95.53M |
| Operating Income | -126.70M |
| Pretax Income | -124.31M |
| Net Income | -124.31M |
| EBITDA | -123.82M |
| EBIT | -126.70M |
| Loss Per Share | -$0.96 |
Full Income StatementBalance Sheet
The company has $128.06 million in cash and $92.54 million in debt, with a net cash position of $35.52 million or $0.59 per share.
| Cash & Cash Equivalents | 128.06M |
| Total Debt | 92.54M |
| Net Cash | 35.52M |
| Net Cash Per Share | $0.59 |
| Equity (Book Value) | 96.92M |
| Book Value Per Share | 1.61 |
| Working Capital | 112.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$122.01 million and capital expenditures -$2.95 million, giving a free cash flow of -$124.96 million.
| Operating Cash Flow | -122.01M |
| Capital Expenditures | -2.95M |
| Depreciation & Amortization | 2.88M |
| Net Borrowing | n/a |
| Free Cash Flow | -124.96M |
| FCF Per Share | -$2.08 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,386.84% |
| Pretax Margin | -1,360.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -129.43% |
| Shareholder Yield | -129.43% |
| Earnings Yield | -184.67% |
| FCF Yield | -185.63% |
Analyst Forecast
The average price target for TCRX is $7.00, which is 600.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 600.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 58.58% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
